Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy

This case series describes the management and outcomes of ocular toxic effects associated with mirvetuximab soravtansine therapy in female patients with folate receptor α–positive gynecologic malignant neoplasms.

Corresponding Author: Edmund Tsui, MD, MS, Jules Stein Eye Institute, University of California, Los Angeles, 200 Stein Plaza, Los Angeles, CA 90095 (etsui@mednet.ucla.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.